Tumor-DCs accumulate lipid and reduce numerically with disease progression.

<p>Mice were inoculated with 5 x 10⁵ AE17 mesothelioma cells and tumors allowed to develop into small (< 40 mm²) or large (> 80 mm²) tumors. Total CD11c⁺ DCs within tumors and lymphoid organs were identified (A) and lipid levels measured using BODIPY staining shown as MFIs of CD11c⁺ DCs; representative samples shown (B). Pooled data show the proportions of CD11c⁺ DCs within tumors (C), spleens (D), dLN (E) and ndLN (F). Pooled data show the lipid content of CD11c⁺ DCs in AE17 tumors (G), spleens (H), dLN (I) and ndLN (J). Lymphoid organs from tumor-bearing mice were compared to those from healthy mice: n = 18 mice with small tumors, n = 9 mice with large tumors and n = 8 healthy control mice. All pooled data are shown as mean ± SEM.